This is the first transaction involving Polisano. The company was founded by Ilie Vonica, 56, who started his private services business almost 20 years ago, but then expanded it both to drug wholesale and to production. His group currently has a turnover of over EUR300 million.
The transaction targeted the shares of Clinica Dialmed SA, which was set up by grouping the nine dialysis clinics of the Polisano Clinic, following a division of the latter.
According to Trade Registry data, Clinica Polisano had a turnover of 68 million lei (EUR15.6 million) last year. The shareholders of Clinica Dialmed S.A. are Ilie Vonica (51%) and Daniela Ioana Vonica (49%), with the share transfer to Diaverum to follow.
According to a ZF estimate, Vonica’s clinics treat over 600 patients, and the valuation of a business in this sector is made based on this indicator. So, if a patient is valued at around EUR25,000, Vonica’s transaction could be put at around EUR15 million. Diaverum representatives confirmed the transaction, without specifying the amount paid.
“Our international expansion is part of our growth strategy. After we entered Chile and Saudi Arabia this year, we are taking the first steps in Romania through the acquisition of Clinica Dialmed,” Diaverum officials told ZF.
Diaverum, based in Munich, Germany, specializes in renal care and has 230 clinics around the world, where it treats around 19,000 patients.
The company made a first step on the Romanian market in 2009, when it set up a joint venture with Romanian company Renamed Farma. At the time, it announced it was aiming for a top position in Romania through acquisitions.
(English version by Daniela Stoican)